|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NID1 |
Gene summary for NID1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NID1 | Gene ID | 4811 |
| Gene name | nidogen 1 | |
| Gene Alias | NID | |
| Cytomap | 1q42.3 | |
| Gene Type | protein-coding | GO ID | GO:0001655 | UniProtAcc | P14543 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 4811 | NID1 | LZE4T | Human | Esophagus | ESCC | 4.52e-04 | 1.76e-01 | 0.0811 |
| 4811 | NID1 | P2T-E | Human | Esophagus | ESCC | 7.21e-39 | 7.71e-01 | 0.1177 |
| 4811 | NID1 | P5T-E | Human | Esophagus | ESCC | 1.75e-08 | 1.53e-01 | 0.1327 |
| 4811 | NID1 | P8T-E | Human | Esophagus | ESCC | 1.37e-02 | 1.48e-01 | 0.0889 |
| 4811 | NID1 | P9T-E | Human | Esophagus | ESCC | 1.37e-03 | 2.73e-01 | 0.1131 |
| 4811 | NID1 | P10T-E | Human | Esophagus | ESCC | 1.83e-52 | 1.08e+00 | 0.116 |
| 4811 | NID1 | P11T-E | Human | Esophagus | ESCC | 4.87e-07 | 2.29e-01 | 0.1426 |
| 4811 | NID1 | P12T-E | Human | Esophagus | ESCC | 1.60e-14 | 2.22e-01 | 0.1122 |
| 4811 | NID1 | P15T-E | Human | Esophagus | ESCC | 8.88e-09 | 3.54e-01 | 0.1149 |
| 4811 | NID1 | P16T-E | Human | Esophagus | ESCC | 6.07e-56 | 1.23e+00 | 0.1153 |
| 4811 | NID1 | P19T-E | Human | Esophagus | ESCC | 1.28e-03 | 4.26e-01 | 0.1662 |
| 4811 | NID1 | P22T-E | Human | Esophagus | ESCC | 2.66e-16 | 3.06e-01 | 0.1236 |
| 4811 | NID1 | P26T-E | Human | Esophagus | ESCC | 2.93e-15 | 3.64e-01 | 0.1276 |
| 4811 | NID1 | P27T-E | Human | Esophagus | ESCC | 6.35e-05 | 1.04e-01 | 0.1055 |
| 4811 | NID1 | P31T-E | Human | Esophagus | ESCC | 2.32e-21 | 3.95e-01 | 0.1251 |
| 4811 | NID1 | P32T-E | Human | Esophagus | ESCC | 5.02e-24 | 4.92e-01 | 0.1666 |
| 4811 | NID1 | P36T-E | Human | Esophagus | ESCC | 1.10e-03 | 3.91e-01 | 0.1187 |
| 4811 | NID1 | P37T-E | Human | Esophagus | ESCC | 5.64e-26 | 7.74e-01 | 0.1371 |
| 4811 | NID1 | P42T-E | Human | Esophagus | ESCC | 3.57e-09 | 4.78e-01 | 0.1175 |
| 4811 | NID1 | P44T-E | Human | Esophagus | ESCC | 3.91e-04 | 3.45e-01 | 0.1096 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003158919 | Esophagus | ESCC | cell-substrate adhesion | 221/8552 | 363/18723 | 3.06e-09 | 6.62e-08 | 221 |
| GO:001081020 | Esophagus | ESCC | regulation of cell-substrate adhesion | 144/8552 | 221/18723 | 3.55e-09 | 7.45e-08 | 144 |
| GO:004578527 | Esophagus | ESCC | positive regulation of cell adhesion | 255/8552 | 437/18723 | 5.07e-08 | 9.11e-07 | 255 |
| GO:001081126 | Esophagus | ESCC | positive regulation of cell-substrate adhesion | 84/8552 | 123/18723 | 3.18e-07 | 4.50e-06 | 84 |
| GO:000716018 | Esophagus | ESCC | cell-matrix adhesion | 141/8552 | 233/18723 | 3.33e-06 | 3.71e-05 | 141 |
| GO:00301984 | Esophagus | ESCC | extracellular matrix organization | 171/8552 | 301/18723 | 6.08e-05 | 4.67e-04 | 171 |
| GO:00430624 | Esophagus | ESCC | extracellular structure organization | 171/8552 | 302/18723 | 7.73e-05 | 5.76e-04 | 171 |
| GO:00452294 | Esophagus | ESCC | external encapsulating structure organization | 172/8552 | 304/18723 | 7.80e-05 | 5.80e-04 | 172 |
| GO:00717115 | Esophagus | ESCC | basement membrane organization | 22/8552 | 31/18723 | 3.90e-03 | 1.58e-02 | 22 |
| GO:00016559 | Esophagus | ESCC | urogenital system development | 177/8552 | 338/18723 | 7.51e-03 | 2.69e-02 | 177 |
| GO:00071606 | Liver | NAFLD | cell-matrix adhesion | 49/1882 | 233/18723 | 4.36e-07 | 2.74e-05 | 49 |
| GO:00108107 | Liver | NAFLD | regulation of cell-substrate adhesion | 47/1882 | 221/18723 | 5.30e-07 | 3.16e-05 | 47 |
| GO:00315896 | Liver | NAFLD | cell-substrate adhesion | 65/1882 | 363/18723 | 2.84e-06 | 1.18e-04 | 65 |
| GO:00108117 | Liver | NAFLD | positive regulation of cell-substrate adhesion | 25/1882 | 123/18723 | 4.73e-04 | 6.74e-03 | 25 |
| GO:001081012 | Liver | Cirrhotic | regulation of cell-substrate adhesion | 88/4634 | 221/18723 | 4.89e-07 | 1.10e-05 | 88 |
| GO:003158912 | Liver | Cirrhotic | cell-substrate adhesion | 128/4634 | 363/18723 | 4.10e-06 | 6.90e-05 | 128 |
| GO:001081112 | Liver | Cirrhotic | positive regulation of cell-substrate adhesion | 53/4634 | 123/18723 | 6.21e-06 | 9.88e-05 | 53 |
| GO:000716011 | Liver | Cirrhotic | cell-matrix adhesion | 85/4634 | 233/18723 | 4.06e-05 | 4.83e-04 | 85 |
| GO:00457857 | Liver | Cirrhotic | positive regulation of cell adhesion | 141/4634 | 437/18723 | 2.05e-04 | 1.89e-03 | 141 |
| GO:0071711 | Liver | Cirrhotic | basement membrane organization | 17/4634 | 31/18723 | 3.19e-04 | 2.77e-03 | 17 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NID1 | SNV | Missense_Mutation | novel | c.724N>A | p.Asp242Asn | p.D242N | P14543 | protein_coding | tolerated(0.18) | benign(0.038) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response |
| NID1 | SNV | Missense_Mutation | rs765670423 | c.1219G>A | p.Ala407Thr | p.A407T | P14543 | protein_coding | tolerated(0.4) | benign(0) | TCGA-A2-A0CP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
| NID1 | SNV | Missense_Mutation | rs765549848 | c.520N>C | p.Gly174Arg | p.G174R | P14543 | protein_coding | tolerated(0.28) | benign(0.011) | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| NID1 | SNV | Missense_Mutation | c.1074G>C | p.Glu358Asp | p.E358D | P14543 | protein_coding | tolerated(0.27) | benign(0.003) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| NID1 | SNV | Missense_Mutation | c.766N>A | p.Gly256Arg | p.G256R | P14543 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AN-A0G0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| NID1 | SNV | Missense_Mutation | c.952N>G | p.Leu318Val | p.L318V | P14543 | protein_coding | tolerated(0.45) | benign(0) | TCGA-AO-A0J6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| NID1 | SNV | Missense_Mutation | rs771262101 | c.2423N>A | p.Pro808Gln | p.P808Q | P14543 | protein_coding | tolerated(0.6) | benign(0.003) | TCGA-AR-A1AY-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unspecific | Doxorubicin | SD |
| NID1 | SNV | Missense_Mutation | c.388A>G | p.Ile130Val | p.I130V | P14543 | protein_coding | tolerated(1) | benign(0) | TCGA-AR-A24Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| NID1 | SNV | Missense_Mutation | novel | c.2639N>A | p.Ala880Glu | p.A880E | P14543 | protein_coding | tolerated(1) | benign(0.001) | TCGA-B6-A40C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | cyclophosphamide | SD |
| NID1 | SNV | Missense_Mutation | rs202192927 | c.326N>T | p.Ala109Val | p.A109V | P14543 | protein_coding | tolerated(0.08) | benign(0.067) | TCGA-BH-A0HA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |